[
    "{\"step_by_step_thinking\": \"Leuprorelin acetate is a luteinizing hormone-releasing hormone (LHRH) agonist and is commonly used as androgen deprivation therapy for prostate cancer. Document [0] states that leuprorelin acetate has been in clinical use for more than 20 years in the palliative treatment of prostate cancer. Document [2] also mentions that leuprorelin acetate is well established as the leading LHRH analog for androgen-deprivation therapy. Additionally, document [10] discusses the use of leuprorelin acetate as a mainstay of androgen deprivation therapy for advanced and metastatic prostate cancer. Therefore, based on the information provided in the documents, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]